BIOMAT Database Logo BIOMAT Database Logo

A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine. 1991

M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Department of Surgery, University of Munich, Klinikum Innenstadt, Germany.

We wanted to determine the effects of WEB 2086, a platelet activating factor (PAF) antagonist, in lipopolysaccharide (LPS) shock in anesthetized pigs. In a randomized study, LPS from S. abortus equi, 2 micrograms/kg/h was given IV for six hours. Thirteen animals received LPS and WEB 2086, 10 mg/kg/h IV for 6.5 hours, beginning 30 minutes before LPS. Eleven septic controls received saline and LPS, three nonseptic controls received saline and WEB 2086, and three nonseptic controls received saline only. In six animals we investigated the effect of synthetic PAF in doses between 50 and 10,000 ng on arterial (AP) and pulmonary arterial (PAP) pressure before and during infusion of WEB 2086. The LPS-induced rise in PAP was reduced by WEB 2086 (p = 0.01) but not the decrease in AP. The LPS-induced leukopenia, hypoxia, increase in airway pressure, and release of plasminogen activator inhibitor were reduced by WEB 2086. Platelet activating factor produced an increase in PAP and a biphasic response in AP. All PAF dose response curves were shifted to the right by WEB 2086. Platelet activating factor was a pulmonary hypertensive agent and contributed to the LPS-induced respiratory alterations.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D011652 Pulmonary Circulation The circulation of the BLOOD through the LUNGS. Pulmonary Blood Flow,Respiratory Circulation,Circulation, Pulmonary,Circulation, Respiratory,Blood Flow, Pulmonary,Flow, Pulmonary Blood,Pulmonary Blood Flows
D011659 Pulmonary Gas Exchange The exchange of OXYGEN and CARBON DIOXIDE between alveolar air and pulmonary capillary blood that occurs across the BLOOD-AIR BARRIER. Exchange, Pulmonary Gas,Gas Exchange, Pulmonary
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Delayed treatment with platelet activating factor receptor antagonist web 2086 attenuates pulmonary dysfunction in porcine endotoxin shock.
November 1994, The Journal of trauma,
M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock.
March 1987, European journal of pharmacology,
M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury.
January 1990, The American journal of physiology,
M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.
February 1989, Thrombosis research,
M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Antagonism of endotoxin-induced disruption of equine gastrointestinal motility with the platelet-activating factor antagonist WEB 2086.
December 1990, Journal of veterinary pharmacology and therapeutics,
M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
June 1987, The Journal of pharmacology and experimental therapeutics,
M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF).
July 1988, Thrombosis research,
M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Protective effect of a platelet-activating factor antagonist (WEB-2086) in postischemic renal failure.
January 1996, Annals of vascular surgery,
M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses.
June 1993, Thorax,
M Siebeck, and J Weipert, and C Keser, and J Kohl, and M Spannagl, and W Machleidt, and L Schweiberer
Effects of WEB 2086, a novel antagonist of platelet activating factor, in active and passive anaphylaxis.
April 1987, Immunopharmacology,
Copied contents to your clipboard!